Skip to main content
LLY
NYSE Life Sciences

FDA Approves Lilly's Inluriyo-Verzenio Combo for ESR1-Mutant Breast Cancer

Tom Rudovsky · Reported by PR Newswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1,144.627
Mkt Cap
$1.078T
52W Low
$712.05
52W High
$1,292.65
52W Position info
61% above low
Off High info
11% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

LLY sits 61% above its 52-week low of $712.05.

Summary

The FDA granted full approval to Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. This is the second approval for Inluriyo in under a year, expanding its label from monotherapy to combination use. In the Phase 3 EMBER-3 trial, the combination doubled median progression-free survival versus Inluriyo alone (11.1 vs 5.5 months, HR=0.53). The approval strengthens Lilly's oncology franchise and provides a new standard-of-care option in a patient population with limited alternatives. The drug is now available in the U.S., and the company is also running the large adjuvant EMBER-4 trial with results expected in 2027.

At the time of this announcement, LLY was trading at $1,144.63 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 17, 2026, 11:18 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,416.23
Real-time Price: $1,399.00 info
Change: -$17.22 (-1%) info
Market Cap: $1.315T info
LLY
Nov 16, 2026, 6:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,455.36
Real-time Price: $1,399.00 info
Change: -$56.36 (-4%) info
Market Cap: $1.315T info
LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,399.00 info
Change: -$53.69 (-4%) info
Market Cap: $1.315T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,399.00 info
Change: -$48.85 (-3%) info
Market Cap: $1.315T info
LLY
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1,411.12
Real-time Price: $1,399.00 info
Change: -$12.12 (-0.86%) info
Market Cap: $1.315T info